The safety and clinical efficacy of
cefoperazone 1 to 2g 12-hourly was evaluated in clinical trials conducted in the United States, Europe, South and Latin America, and Japan. 1046 patients were treated in 4 comparative and 9 non-comparative studies. An overall satisfactory clinical response for
cefoperazone therapy was achieved in 540 (88%) of the 615 evaluable patients.
Cefoperazone was effective in 92% of lower
respiratory tract infections, 81% of
urinary tract infections, 98% of gynaecological
infections and 90% of a mixture of intra-abdominal,
wound and
soft tissue infections. A satisfactory clinical response was obtained in over 90% of patients infected with organisms normally susceptible to
cephalosporins, such as staphylococci, streptococci, Escherichia coli, Klebsiella and Proteus species. 50 to 90% of
infections caused by organisms resistant to presently available
cephalosporins, such as Enterobacter species, Proteus vulgaris, Providencia species, Morganella morganii, Serratia species, Pseudomonas aeruginosa, and Bacteroides fragilis responded satisfactorily to
cefoperazone. In the 4 clinical trials comparing
cefoperazone with
cefamandole,
cephazolin or
carbenicillin,
cefoperazone therapy resulted in a similar or higher rate of satisfactory clinical response. Adverse reactions related to
cefoperazone occurred in 8% of patients and were mainly diarrhoea (4%), skin reactions (3%) and
phlebitis (1%). Twice daily dosing with
cefoperazone appears to be effective against numerous Gram-positive and Gram-negative bacteria in a variety of clinical
infections.